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Abstract
Background and Objectives Limited data are available
regarding the use of golimumab (100 mg) every 4 weeks,
with or without methotrexate (MTX). The aim of this retro-
spective analysis was to evaluate the effectiveness and safety
of golimumab following usual clinical practice in Japanese
patients with rheumatoid arthritis (RA) according to the
recommendations given in the Japanese package insert.
Patients and Methods Japanese RA patients with mod-
erate-to-high disease activity, according to the 28-joint
disease activity score based on C-reactive protein (DAS28-
CRP) criteria, despite treatment with MTX or another
biological agent, were enrolled. Patients were assigned to
50 mg golimumab plus MTX or 100 mg golimumab
monotherapy every 4 weeks for 24 weeks. All patients
were given MTX if it was not contraindicated. The primary
endpoint was the proportion of patients achieving clinical
remission (defined as a DAS28-CRP \2.3 or a simplified
disease activity index [SDAI] score \3.3) at 24 weeks.
Results Most patients received combined 50 mg goli-
mumab plus MTX (41/43). In these patients, the primary
endpoint, clinical remission, was attained in 83 % of
patients according to DAS28-CRP criteria (p \ 0.001) and
69 % according to SDAI criteria (p \ 0.001) by week 24.
Adverse events were reported in 11.6 % of patients
receiving golimumab.
Conclusions Golimumab (50 mg) plus MTX effectively
reduced the signs and symptoms of RA and was generally
well tolerated in patients with an inadequate response to
MTX and other biological agents.
1 Introduction
In recent years, methotrexate (MTX) therapy at high dose
levels and tumor necrosis factor (TNF) inhibitor therapy
have been applied to treatment of rheumatoid arthritis
(RA). Anti-TNF therapy, either alone or in combination
with MTX (apart from infliximab, which should only be
used in combination with MTX), is recommended in
patients with active RA with inadequate response to MTX
or another disease-modifying antirheumatic drug
(DMARD) or combination of DMARDs or another anti-
TNF agent [1–3]. These new methods of treatment are
expected to yield not only the alleviation of disease
activity, but also structural improvement of the affected
joints and improvement in daily life for patients. The three
most widely used anti-TNF agents in Japan are infliximab,
etanercept, and adalimumab, and numerous reports have
been published on these agents [4–6].
Golimumab (GLM), a new human anti-TNF antibody
agent created using transgenic mice, has been shown to
exert effectiveness comparable to that of existing anti-TNF
antibody agents when injected subcutaneously at 4-week
intervals [7–13]. This drug was introduced in Japan in
September 2011, thus providing a new treatment option for
Japanese patients with RA. GLM can be administered
either as monotherapy at a dosage of 100 mg or in com-
bination with MTX at dosages of 50 or 100 mg every
4 weeks [14]. It is indicated not only in patients who have
not previously received treatment with biological agents
but also in patients who have experienced difficulties with
infliximab or adalimumab therapy; for example, problems
with neutralizing antibodies.
In Japan, there have been no published reports on the
use of GLM in clinical practice to date. When patients are
enrolled into clinical studies, age and disease activity are
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often taken into account to ensure safety and continued use
of the investigational agent, so the populations studied
differ from the population managed in real life. Therefore,
this analysis evaluates the use of GLM in patients with RA
receiving real-life clinical care at our clinic.
2 Methods
2.1 Subjects
This retrospective analysis included patients with baseline
moderate-to-high disease activity according to a 28-joint
disease activity score based on C-reactive protein (DAS28-
CRP) [3.2 despite treatment with MTX or another bio-
logical agent. Patients had RA according to American
College of Rheumatology (ACR) criteria [15] and had
received GLM treatment as outpatients at our hospital, the
Shono Rheumatology Clinic, Fukuoka, Japan, between
September 2011 and April 2012. Consent in writing was
obtained from each patient in advance.
2.2 Treatment
Patients received combination therapy with GLM plus
MTX, with GLM administered at a dose of 50 mg or
100 mg every 4 weeks plus MTX administered at a dose of
up to 8 mg/week; or GLM monotherapy, with GLM
administered at 100 mg every 4 weeks, for a total of
24 weeks. All patients were prescribed MTX if it was not
contraindicated. GLM was administered subcutaneously in
accordance with the Japanese package insert [14].
2.3 Outcome Measures
The primary endpoint of this retrospective analysis of
effectiveness was to evaluate the proportion of patients
achieving remission defined as a DAS28-CRP \2.3 or a
simplified disease activity index (SDAI) score \3.3. Mean
changes in the DAS28-CRP from baseline to 4 weeks were
also evaluated.
Safety was evaluated on the basis of adverse events and
laboratory test data. For each parameter, additional strati-
fied analyses were conducted, dividing the patients into two
groups; that is, bio-naı¨ve patients who had not received
biological agents prior to receiving GLM, and patients who
had received prior biological agents (i.e., those switching
from other biological agents to GLM).
2.4 Statistical Analysis
All data were included for efficacy and safety analyses.
The last observation carried forward (LOCF) method was
used to allow for missing data. Comparison of groups was
performed using the Student’s t test with statistical sig-
nificance set at p \ 0.05.
3 Results
3.1 Patient Baseline Demographics and Clinical
Characteristics
Of all patients studied, 18 were bio-naı¨ve cases and 25 had
received prior biological agents, including infliximab
(n = 4), etanercept (n = 10), adalimumab (n = 6), and
tocilizumab (n = 5). Of the 25 patients previously treated
with biological agents, 19 had received one prior biological
agent and 6 had received two or more agents.
Table 1 shows the baseline demographics and disease
characteristics of the patients enrolled into the study.
Patient characteristics were generally well balanced
between bio-naı¨ve patients and those who had received a
prior biological agent, except the proportion of women was
slightly greater (96.0 vs 83.3 %) and disease duration was
slightly longer (122.6 vs 105.3 months) in the bio-switch-
ing group.
3.2 Interventions
In total, 41 patients received GLM at a dose of 50 mg
every 4 weeks in combination with MTX (mean dose
6.23 mg/week) and 2 patients received GLM monotherapy
at a dose of 100 mg every 4 weeks. Four patients were
unsatisfied with the inconvenience of self-injection and
injection pain of prior biological treatment, despite suffi-
cient clinical response; therefore, those patients in clinical
remission at baseline were switched to GLM treatment as a
result of patients’ wishes. Of the 43 patients, 35 completed
the 24-week treatment period.
3.3 Effectiveness
Remission rates, defined as the proportion of patients
achieving a DAS28-CRP \2.3 and an SDAI score \3.3,
steadily improved over the course of treatment with GLM
(Fig. 1). After 8 weeks of treatment, 71.4 % of patients
achieved a DAS28-CRP \2.3 and 50.0 % achieved an
SDAI score\3.3. After 8 weeks of treatment, the DAS28-
CRP and SDAI remission rates were higher in patients who
had not received prior biological agents versus those who
had (55.6 vs 50.0 % and 61.1 vs 41.7 %, respectively).
The mean DAS28-CRP 4 weeks after the start of treat-
ment was significantly improved compared with the pre-
treatment score [mean DAS28-CRP at week 4 = 1.80 vs
4.14 (range 1.28–7.04) at baseline; p \ 0.001].
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Improvements in DAS28-CRP and SDAI scores throughout
the treatment period were similar in bio-naı¨ve patients and
those who had received prior biological agents (Figs. 2, 3).
Changes in DAS28-CRP and SDAI scores at 4 and 8 weeks
were statistically significant compared with baseline in
both bio-naı¨ve patients and those who had received prior
biological agents (all p \ 0.001).
3.4 Tolerability
GLM was generally well tolerated with no unexpected
safety issues observed. Adverse events (shown in Table 2)
were reported in five patients, most of whom were
receiving GLM (50 mg) in combination with MTX (6 or
8 mg). Two patients reported fractures (one ankle and one
femur); one patient was hospitalized due to renal impair-
ment, chest pain, dyspnea, bronchial asthma, acute upper
respiratory tract inflammation, and bronchitis; one patient
(treated with GLM monotherapy at 100 mg) experienced
venous thromboembolism and lower limb edema; and one
patient reported renal impairment, hepatic function, and
nephrogenic anemia. Consistent with other GLM safety
data reported in Japanese clinical trials, no unknown
adverse event was reported in this clinical analysis. All
adverse events were resolved with treatment.
Table 1 Baseline demographics and disease characteristics in bio-naı¨ve patients and patients who had received prior biological agents
Total (n = 43) Bio-naı¨ve (n = 18) Prior biologicals (n = 25)
Sex [n (%)]
Female 39 (90.7) 15 (83.3) 24 (96.0)
Male 4 (9.3) 3 (16.7) 1 (4.0)
Age [years] 59.1 (32–79) 55.8 (37–79) 61.4 (32–76)
Disease duration [months] 115.3 (7–708) 105.3 (7–708) 122.6 (12–252)
DAS28-CRP 4.14 (1.28–7.04) 4.16 (2.61–6.39) 4.12 (1.28–7.04)
SDAI 22.2 (2.81–62.30) 22.30 (6.70–56.29) 22.20 (2.81–62.30)
CDAI 20.92 (2.50–60.90) 20.94 (6.50–56.00) 20.90 (2.50–60.90)
Tender joint count [0–68] 6.3 (0–24) 6.7 (1–22) 6.0 (0–24)
Swollen joint count [0–68] 5.9 (0–22) 5.4 (0–18) 4.8 (0–22)
mHAQ [0–24] 0.65 (0–2) 0.44 (0–2) 0.72 (0–2)
CRP [mg/dL] 1.5 (0.1–13.5) 1.6 (0.1–13.5) 1.4 (0.1–8.4)
RF positive [n (%)] 34 (79.0) 13 (72.2) 21 (84.0)
ACPA positive [n (%)] 22 (51.1) 11 (61.1) 11 (44.0)
All values are presented as means with ranges given in parentheses unless specified otherwise
ACPA anti-citrullinated protein autoantibody, CDAI clinical disease activity index, CRP C-reactive protein, DAS28-CRP disease activity score
28 based on C-reactive protein, mHAQ modified health assessment questionnaire; RF rheumatoid factor, SDAI simplified disease activity index
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Fig. 1 Remission rate in 43 patients with rheumatoid arthritis treated
with golimumab alone or in combination with methotrexate. Remis-
sion was defined as a 28-joint disease activity score based on
C-reactive protein (DAS28-CRP) of \2.3 or a simplified disease
activity index (SDAI) score of \3.3. DAS28-CRP remission and
DAS28-CRP plus SDAI remission (ALL) are shown. BL baseline,
W weeks
Fig. 2 Changes in mean 28-joint disease activity score based on
C-reactive protein (DAS28-CRP) in bio-naı¨ve or previously treated
patients with rheumatoid arthritis receiving golimumab alone or in
combination with methotrexate. The dashed line represents the
defined remission cutoff value of 2.3. BL baseline, W weeks
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4 Discussion
The present analysis in Japanese patients with RA in real-
life clinical care revealed high effectiveness and safety of
GLM alone or in combination with MTX, with significant
improvements in mean DAS28-CRP and SDAI scores
observed in bio-naı¨ve patients 16 weeks after the start of
treatment (p \ 0.001). The reason for the high remission
rate was considered to be the difference in average patient
body weight between western countries and Japan (75 vs
50 kg, respectively).
These effectiveness data are consistent with efficacy data
from clinical studies [7–10, 12, 13, 16]. Most GLM studies
are designed to permit rescue of patients at 16 weeks with
alternative pharmacological therapy for those meeting the
nonresponse criteria for early escape [8–10, 12, 13].
Similar to the GO-FORTH study [13], our clinical
analysis involved patients treated with MTX at 8 mg/week,
which is the maximum dose approved in Japan at the time
that the patients were receiving treatment [17]. This is
lower than the current recommended MTX dose in RA [3,
14, 18] and lower than the MTX dose used in combination
with GLM in other published studies [7, 9, 10]. Despite the
low doses of MTX used, overall remission rates with GLM
were high. Evidence suggests that, for patients receiving
MTX who fail to achieve clinical remission based on SDAI
or disease activity score scales, increasing the MTX dose
needs to be considered at this time [17]. In the GO-FOR-
WARD study, GLM was shown to be effective in patients
who showed lower responses or who were refractory to
prior MTX therapy [9, 10].
In the present retrospective analysis, manifestation of
effectiveness appeared to be delayed in the bio-switching
group compared with the bio-naı¨ve group, suggesting the
necessity for longer follow-up when evaluating effective-
ness in patients who switch between biological therapies.
In a post-hoc analysis of the effectiveness in relation to
the reasons for switching, the effectiveness did not differ
significantly according to the reason (data not shown). This
suggests that patients undergoing switching will respond to
this therapy, regardless of the reasons for switching. This
supports findings by Smolen et al. [12] that switching from
other anti-TNF agents to GLM was effective regardless of
the reasons for switching, indicating that GLM can serve as
the second anti-TNF agent when patients are switched from
another TNF agent. Of the five anti-TNF agents available,
including certolizumab pegol, all have different affinities to
TNF-a; therefore, switching from one anti-TNF agent to
another is likely to be effective.
Expression of antibodies to anti-TNF antibody agents
such as infliximab, adalimumab, and certolizumab pegol
monotherapy is not uncommon; however, incidences of
anti-GLM antibodies in the GO-FORWARD [9] and GO-
FORTH [13] studies were remarkably low. Because GLM
is prepared by the transgenic mouse technique, it is an
antibody with high affinity for the antigen [19], which
means that formation of unstable proteins or aggregations,
which can serve as immunogens, is unlikely. Studies of
GLM (100 mg) monotherapy were conducted in Caucasian
and South American countries in GO-FORWARD [9, 10]
and in Japan in GO-FORTH [13] and GO-MONO [16], and
showed that GLM is an appropriate biological agent for
preventing the loss of effectiveness in Caucasian, South
American, and Japanese populations receiving long-term
RA treatment [9, 10, 13, 16]. As a result of findings from
the GO-FORTH [13] and GO-MONO [16] studies, in
addition to the 50-mg dose, GLM (100 mg) every
4 weeks—as monotherapy and in combination with
MTX—has been approved in Japan. Further studies at this
dose level in larger numbers of patients are necessary.
Apart from the usual limitations relating to observa-
tional data and retrospective analyses, particularly with
Fig. 3 Changes in mean simplified disease activity index (SDAI)
score in bio-naı¨ve or previously treated patients with rheumatoid
arthritis receiving golimumab alone or in combination with metho-
trexate. The dashed line represents the defined remission cutoff value
of 3.3. BL baseline, W weeks
Table 2 Adverse events and course reported in five patients with
rheumatoid arthritis treated with golimumab every 4 weeks for
24 weeks
Case Adverse events Course
1 Ankle fracture Treated by
another clinic
2 Femur fracture Treated by
another clinic
3 Renal impairment, chest pain, dyspnea,




4 Embolism venous, edema lower limb Resolved, in
remission




regard to selection and enrolment bias, a major limitation
of our analysis is the small patient numbers, especially for
patients receiving GLM (100 mg) monotherapy. In addi-
tion, evaluation of levels of anti-GLM antibodies and the
effects of GLM on structural joint damage in this real-life
setting would have been useful; however, this was not
evaluated in the original study.
Despite suppression of joint destruction being an impor-
tant factor in improving the quality of life of patients with
RA, the number of published reports evaluating this effect in
patients treated with GLM is small, because of its relatively
recent development. Emery et al. [7] reported that treatment
with GLM suppressed joint destruction significantly
52 weeks after the start of treatment, and further long-term
observation is needed. However, due to the short follow-up
period in our analysis, such observation was not possible.
In the present analysis, there were no serious adverse
events arising from the use of GLM, although deterioration
in renal function was reported in two patients. An associ-
ation with the development of malignant tumors has been
suggested with GLM, and further clinical confirmation is
warranted [20]. However, long-term observation of the
patients in our study is needed before any definite con-
clusions can be made.
It is important to select a type of biological agent taking
into account the lifestyle of individual patients. Despite
reported problems with pain and administration site reac-
tions, subcutaneous injection of drugs offers greater con-
venience than intravenous infusion, which requires
physical immobilization for many hours at a hospital, and a
longer dosing interval is also advantageous. Because GLM
contains only small amounts of stimulating acidic additives
and requires only a small volume of dosing solution,
reported incidences of pain and administration site reac-
tions are low [14].
5 Conclusion
In the present analysis, GLM plus MTX or GLM mono-
therapy used in clinical practice in Japanese patients with
RA was confirmed to have high effectiveness and safety,
comparable with existing biological agents. Thus, we
conclude that GLM is a promising new alternative for the
treatment of RA in Japanese patients showing poor
response, those in whom the use of other biological agents
is contraindicated, and cases where the use of MTX in
combination with biological agents is difficult.
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